The effect of ASPH inhibitors on EMT-associated markers is consistent with previous findings in which ASPH inactivation strategies, such as targeting with miR-200a 35, knocking out with CRISPR/Cas9 15,25, silencing with shRNA 23, or disrupting catalytic activity with SMI 15 have demonstrated EMT suppression in cancer cells. Here, ASPH is linked to cancer.